Hansa Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	552.81	701.08	405.28
Cash & Short-Term Investments	552.81	701.08	405.28
Cash Growth	55.98%	72.99%	-
Accounts Receivable	65.98	53.87	26.78
Other Receivables	64.2	13.43	15.11
Total Trade Receivables	130.18	67.3	41.89
Inventory	7.96	6.13	2.61
Other Current Assets	-	22.1	17.47
Total Current Assets	690.95	796.61	467.24
Net Property, Plant & Equipment	8.04	13.35	17.88
Other Intangible Assets	247.05	230.56	197.33
Other Long-Term Assets	124.76	126.25	118.19
Total Assets	1,071	1,167	800.64
Accounts Payable	70.57	54.06	37.62
Accrued Expenses	107.83	121.14	108.99
Short-Term Debt	300.85	136.87	-
Current Portion of Leases	4.34	8.28	7.68
Unearned Revenue	-	-	16.33
Other Current Liabilities	70.8	90.32	85.06
Total Current Liabilities	554.39	410.66	255.69
Long-Term Debt	726.45	790.53	1,065
Long-Term Leases	2.16	3	6.68
Other Long-Term Liabilities	308.04	51.57	63.47
Total Long-Term Liabilities	1,037	845.1	1,135
Total Liabilities	1,591	1,256	1,390
Common Stock	-	101.76	67.81
Treasury Stock	-	-2.03	-2.36
Additional Paid-in Capital	-	4,457	3,454
Accumulated Other Comprehensive Income	-	-2.03	0.94
Retained Earnings	-	-4,644	-4,110
Total Common Shareholders' Equity	-	-88.99	-589.83
Shareholders' Equity	-520.24	-88.99	-589.83
Total Liabilities & Equity	1,071	1,167	800.64
Total Debt	1,034	938.67	1,079
Net Cash (Debt)	-480.99	-237.59	-673.73
Net Cash Per Share	-4.93	-2.93	-10.72
Book Value	-	-88.99	-589.83
Book Value Per Share	-	-1.10	-9.39
Tangible Book Value	-247.05	-319.55	-787.17
Tangible Book Value Per Share	-2.53	-3.94	-12.53